AIMS/HYPOTHESIS: Heterozygous mutations in the gene of the transcription factor hepatocyte nuclear factor 4alpha (HNF-4alpha) are considered a rare cause of MODY with only 14 mutations reported to date. The description of the phenotype is limited to single families. We investigated the genetics and phenotype of HNF-4alpha mutations in a large European Caucasian collection. METHODS: HNF-4alpha was sequenced in 48 MODY probands, selected for a phenotype of HNF-1alpha MODY but negative for HNF-1alpha mutations. Clinical characteristics and biochemistry were compared between 54 HNF-4alpha mutation carriers and 32 familial controls from ten newly detected or previously described families. RESULTS: Mutations in HNF-4alpha were found in 14/48 (29%) probands negative for HNF-1alpha mutations. The mutations found included seven novel mutations: S34X, D206Y, E276D, L332P, I314F, L332insCTG and IVS5nt+1G>A. I314F is the first reported de novo HNF-4alpha mutation. The average age of diagnosis was 22.9 years with frequent clinical evidence of sensitivity to sulphonylureas. Beta cell function, but not insulin sensitivity, was reduced in diabetic mutation carriers compared to control subjects (homeostasis model assessment of beta cell function 29% p<0.001 vs controls). HNF-4alpha mutations were associated with lower apolipoprotein A2 (p=0.001), A1 (p=0.04) and total HDL-cholesterol (p=0.02) than in control subjects. However, in contrast to some previous reports, levels of triglycerides and apolipoprotein C3 were normal. CONCLUSIONS/ INTERPRETATION: HNF-4alpha mutations are common when no HNF-1alpha mutation is found in strictly defined MODY families. The HNF-4alpha clinical phenotype and beta cell dysfunction are similar to HNF-1alpha MODY and are associated with reduced apolipoprotein A2 levels. We suggest that sequencing of HNF-4alpha should be performed in patients with clinical characteristics of HNF-1alpha MODY in whom mutations in HNF-1alpha are not found.
AIMS/HYPOTHESIS: Heterozygous mutations in the gene of the transcription factor hepatocyte nuclear factor 4alpha (HNF-4alpha) are considered a rare cause of MODY with only 14 mutations reported to date. The description of the phenotype is limited to single families. We investigated the genetics and phenotype of HNF-4alpha mutations in a large European Caucasian collection. METHODS:HNF-4alpha was sequenced in 48 MODY probands, selected for a phenotype of HNF-1alpha MODY but negative for HNF-1alpha mutations. Clinical characteristics and biochemistry were compared between 54 HNF-4alpha mutation carriers and 32 familial controls from ten newly detected or previously described families. RESULTS: Mutations in HNF-4alpha were found in 14/48 (29%) probands negative for HNF-1alpha mutations. The mutations found included seven novel mutations: S34X, D206Y, E276D, L332P, I314F, L332insCTG and IVS5nt+1G>A. I314F is the first reported de novo HNF-4alpha mutation. The average age of diagnosis was 22.9 years with frequent clinical evidence of sensitivity to sulphonylureas. Beta cell function, but not insulin sensitivity, was reduced in diabetic mutation carriers compared to control subjects (homeostasis model assessment of beta cell function 29% p<0.001 vs controls). HNF-4alpha mutations were associated with lower apolipoprotein A2 (p=0.001), A1 (p=0.04) and total HDL-cholesterol (p=0.02) than in control subjects. However, in contrast to some previous reports, levels of triglycerides and apolipoprotein C3 were normal. CONCLUSIONS/ INTERPRETATION:HNF-4alpha mutations are common when no HNF-1alpha mutation is found in strictly defined MODY families. The HNF-4alpha clinical phenotype and beta cell dysfunction are similar to HNF-1alpha MODY and are associated with reduced apolipoprotein A2 levels. We suggest that sequencing of HNF-4alpha should be performed in patients with clinical characteristics of HNF-1alpha MODY in whom mutations in HNF-1alpha are not found.
Authors: M M Byrne; J Sturis; S S Fajans; F J Ortiz; A Stoltz; M Stoffel; M J Smith; G I Bell; J B Halter; K S Polonsky Journal: Diabetes Date: 1995-06 Impact factor: 9.461
Authors: E H Hani; L Suaud; P Boutin; J C Chèvre; E Durand; A Philippi; F Demenais; N Vionnet; H Furuta; G Velho; G I Bell; B Laine; P Froguel Journal: J Clin Invest Date: 1998-02-01 Impact factor: 14.808
Authors: Ewan R Pearson; Bryan J Starkey; Roy J Powell; Fiona M Gribble; Penny M Clark; Andrew T Hattersley Journal: Lancet Date: 2003-10-18 Impact factor: 79.321
Authors: A M Møller; L T Dalgaard; L Ambye; L Hansen; O Schmitz; T Hansen; O Pedersen Journal: J Clin Endocrinol Metab Date: 1999-01 Impact factor: 5.958
Authors: A Stride; M Vaxillaire; T Tuomi; F Barbetti; P R Njølstad; T Hansen; A Costa; I Conget; O Pedersen; O Søvik; R Lorini; L Groop; P Froguel; A T Hattersley Journal: Diabetologia Date: 2002-03 Impact factor: 10.122
Authors: Silva Arslanian; Laure El Ghormli; Morey H Haymond; Christine L Chan; Steven D Chernausek; Rachelle G Gandica; Rose Gubitosi-Klug; Lynne L Levitsky; Maggie Siska; Steven M Willi Journal: Pediatr Diabetes Date: 2020-03-03 Impact factor: 4.866
Authors: Jacklyn N Hellwege; Pamela J Hicks; Nicholette D Palmer; Maggie C Y Ng; Barry I Freedman; Donald W Bowden Journal: J Diabetes Metab Date: 2011-10-20
Authors: Rebecca Mar-Heyming; Makoto Miyazaki; Daphna Weissglas-Volkov; Nicholas A Kolaitis; Narimaan Sadaat; Christopher Plaisier; Päivi Pajukanta; Rita M Cantor; Tjerk W A de Bruin; James M Ntambi; Aldons J Lusis Journal: Arterioscler Thromb Vasc Biol Date: 2008-03-13 Impact factor: 8.311
Authors: Daniela Gasperíková; Nicolas D Tribble; Juraj Staník; Miroslava Hucková; Nadezda Misovicová; Martijn van de Bunt; Lucia Valentínová; Beryl A Barrow; L'ubomir Barák; Radoslav Dobránsky; Eva Bereczková; Jozef Michálek; Kate Wicks; Kevin Colclough; Julian C Knight; Sian Ellard; Iwar Klimes; Anna L Gloyn Journal: Diabetes Date: 2009-05-01 Impact factor: 9.461